Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α

Abstract

Corresponding Author: C. Marcela Diaz-Montero, Ph.D., Department Immunology, Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195. Conflict of interest: BR has received consulting fees from and performed contracted research for Bristol-Myers Squibb, GlaxoSmithKline, Merck, and Pfizer. Additionally, he has performed contracted research for Genentech. The remaining authors declare no conflict of interest. HHS Public Access Author Manuscript Author ManuscriptAuthor Manuscript Author ManuscriptPurpose-Little is known about the association between MDSC subsets and various chemokines in patients with RCC, or the factors that draw MDSC into tumor parenchyma.Experimental Design-We analyzed PMN-MDSC, M-MDSC and I-MDSC from the parenchyma and peripheral blood of 48 RCC patients, isolated at nephrectomy. We analyzed levels of IL-1β, IL-8, CXCL5, Mip-1α, MCP-1 and Rantes. Furthermore, we performed experiments in a Renca murine model to assess therapeutic synergy between CXCL2 and anti-PD1, and to elucidate the impact of IL-1β blockade on MDSC. Results-Parenchymal

Dynamics of blood neutrophil‐related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non‐small cell lung cancer: A hypothesis‐generating study

“…In contrast, our previous studies showed that the presence of a few PD‐1 + TILs was associated with the response to salvage chemotherapy, as well as nivolumab treatment . However, we did not clarify why preceding nivolumab therapy showed less antitumor activity in the responders to salvage chemotherapy.…”

“…Circulating MDSC levels were inversely associated with response rate and survival after treatment with nivolumab in cancer patients . In tumor‐bearing mouse models, the chemokine‐related substances that recruit neutrophils and MDSCs into the tumor suppressed the antitumor activity of PD‐1 blockade …”

Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis

“…The presence of granulocytes in the low‐density mononuclear fraction of peripheral blood in cancer patients has been previously reported in RCC, HNC, pancreatic cancer, colon cancer and breast adenocarcinoma patients…”

“…The presence of granulocytes in the low-density mononuclear fraction of peripheral blood in cancer patients has been previously reported in RCC, 29 HNC, 19 pancreatic cancer, colon cancer and breast adenocarcinoma patients. 18 We assessed the presence of LDN in lung cancer patients at early and advanced stages compared to COPD patients and healthy volunteers ( Table 1).…”

Immunotherapy for osteosarcoma: Where do we go from here?

“…The mechanisms behind the tumor cell evasion include loss of tumor antigen expression, downregulation of human leukocyte antigens (HLA) from cancer cell surfaces, and recruitment of T‐regulatory cells (Tregs), myeloid derived suppressor cells, or tumor‐associated M2 macrophages, which all increase immunosuppression. These changes may lead to the upregulation of inhibitory receptors (e.g., cytotoxic T‐lymphocyte associated protein‐4 [CTLA‐4], PD‐1) on T cells, or of inhibitory ligands (e.g., PD‐L1) on tumor cells . Immunotherapies aim to counteract this escape phase and reinvigorate the patient's immune system to recognize and destroy cancerous cells.…”